Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Abingdon Health PLC on Tuesday reported a narrowed loss amid higher revenue and decreased costs, as it focuses on shifting away from Covid products.
The York-based lateral flow contract development and manufacturing company said pretax loss in the financial year that ended on June 30 narrowed to £3.6 million from £21.6 million a year prior. Revenue climbed 43% to £4.0 million from £2.8 million. Cost of sales decreased to £2.0 million from £6.4 million, while administrative costs were 21% lower at £5.2 million from £6.6 million.
The company said its focus is as a fully integrated lateral flow contract research organisation/contract development and manufacturing organization following its transition away from Covid-19 products. ‘We remain highly focused on continuing to grow our revenues and reducing our cash-burn in FY24 and beyond,’ said Chief Executive Officer Chris Yates.
Abingdon Health shares fell 13% to 11.35 pence each on Tuesday morning in London.
Copyright 2023 Alliance News Ltd. All Rights Reserved.